| | 850140-72-6 Basic information More.. |
| Product Name: | Afatinib | | Synonyms: | Afatinib;(2E)-N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-2-butenamide;4-[(3-chloro-4-fluorophenyl)aMino]-6-{[4-(N,N-diMethylaMino)-1-oxo-2-buten-1-yl]aMino}-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline;2-ButenaMide, N-[4-[(3-chloro-4-fluorophenyl)aMino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(diMethylaMino)-, (2E)-;(S,E)-N-(4-((3-Chloro-4-fluorophenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)-4-(dime;Afatinib API;Afatinib(BIBW2992MA2);GILOTRIF(AFATINIB) | | CAS: | 850140-72-6 | | MF: | C24H25ClFN5O3 | | MW: | 485.94 | | EINECS: | | | Mol File: | 850140-72-6.mol |  |
Use
Afatinib is a prescription medicine that can be taken orally for the treatment of non-small cell lung cancer (NSCLC) with atypical Epidermal Growth Factor Receptor (EFGR) agents. Afatinib is also prescribed for the treatment of NSCLC with the potential or radiating to other body tissues other than the lungs (metastatic cancer) as detected through an FDA approved examination. Afatinib is a 4-anilinoquinazoline tyrosine kinase suppressor that is available as a dimaleate salt (brand name: Giltrif). The drug is the first FDA-endorsed oncology product by Boehringer Ingelheim.
- Afatinib
-
- US $25.00 / kg
- 2024-04-15
- CAS:850140-72-6
- Min. Order: 1kg
- Purity: 99%
- Supply Ability: 50000tons
- Afatinib
-
- US $0.00-0.00 / kg
- 2023-12-20
- CAS:850140-72-6
- Min. Order: 1kg
- Purity: 99%，single impurity＜0.1
- Supply Ability: 1 ton
- Afatinib
-
- US $10.00 / kg
- 2023-07-31
- CAS:850140-72-6
- Min. Order: 20kg
- Purity: 99.95%
- Supply Ability: 500tons
|
|
850140-72-6
Recommend Suppliers |
|